date:Sep 14, 2012
tient safety and ensure continued research and development of new cures and treatments, said Eisenberg. However, he pointed out that India needs to recognise scientific differences between small molecule therapeutics and biologics. The US industry represented by BIO urged the Government of India to include substantial non-patent data exclusivity in its policy and respect intellectual property and other legal rights. All participants agreed that there is scope for continued discussion and collabo